On November 12, 2021, the State Food and Drug Administration announced that Hunan Mingrui Pharmaceutical Co., LTD., Propofol fumarate tenofovir tablets were approved successfully! This variety is completed by Duzheng Biological "one-stop" clinical research. (The strategic cooperative unit, Hunan Occupational Disease Prevention And Control Institute, is responsible for clinical practice, she Tong Intelligence is responsible for recruitment, First lead medicine is responsible for SMO service, weight counter data execution data management and statistical analysis). Clinical and analysis of this product are exempt from on-site verification.
Propofol Tenofovir Fumarate (TAF), known as "the strongest hepatitis B drug in history", is a blockbuster hepatitis B product developed by Gilead. The drug was first approved in November 2016 in the United States under the brand name "Vemlidy", and was subsequently approved in Japan, the European Union and Canada. On November 8, 2018, it was approved to be marketed in China for the treatment of chronic hepatitis b (HBV) in adults and adolescents (over 12 years old and at least 35kg in weight). Its Chinese commercial name is "veridide", also known as tenofovir ii, which marks the simultaneous access of Chinese patients with chronic hepatitis b and patients in Europe and the United States to global innovative drugs. In November 2019, TAF negotiated to be included in the National Medical insurance Category B directory.
The company will continue to adhere to the "customer-centric" service concept, to provide domestic partners with clinical research "one-stop" service. From recruitment, clinical, analysis, data, each link seamless, the whole process of information management mode, to ensure that the study of high quality and efficient completion!